drugset / Trial / NCT04688151
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
Phase 1
Active not recruiting
22 enrolled
National Health Research Institutes, Taiwan
Chang Gung Memorial Hospital · collabChina Medical University Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
Timeline
- Start
- 2021-02-22
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |